PMID- 19780860
OWN - NLM
STAT- MEDLINE
DCOM- 20100818
LR  - 20221207
IS  - 1468-1293 (Electronic)
IS  - 1464-2662 (Linking)
VI  - 11
IP  - 3
DP  - 2010 Mar
TI  - Prospective epidemiological study of the prevalence of human leukocyte antigen 
      (HLA)-B*5701 in HIV-1-infected UK subjects.
PG  - 187-92
LID - 10.1111/j.1468-1293.2009.00762.x [doi]
AB  - OBJECTIVES: Human leukocyte antigen (HLA)-B(*)5701 is strongly associated with 
      developing a hypersensitivity reaction to abacavir (ABC) in White and Hispanic 
      subjects. Across the UK, limited data exist on HLA-B(*)5701 prevalence in 
      HIV-1-infected subjects. We determined HLA-B(*)5701 prevalence in the general 
      HIV-1-infected population and in specific ethnic groups, particularly Black 
      Africans who, in general, exhibit greater genetic diversity. We also compared 
      HLA-B(*)5701 results obtained from local laboratories with those from a central 
      provider. DESIGN AND METHODS: Multi-centre, observational study. All 
      HIV-1-infected adult individuals receiving care at participating centres were 
      eligible, irrespective of treatment status or prior exposure to ABC. Subjects 
      provided samples for HLA-B(*)5701 assessment by both local (blood) and central 
      laboratories (buccal swabs). HLA-B(*)5701 prevalence was adjusted to represent 
      the ethnic group composition of the general UK population, and by main ethnic 
      group. RESULTS; From eight UK centres, 1494 subjects [618 (41%) White, 770 (52%) 
      Black] were recruited. Eighty-nine per cent of Black subjects reported an 
      immediate country of origin in Africa. Overall adjusted HLA-B(*)5701 prevalence 
      was 4.55% [95% confidence interval (CI) 3.49% to 5.60%]. Among White subjects, 
      prevalence was 7.93% (CI 5.80% to 10.06%). Among Black subjects, only two (both 
      Ugandan) were HLA-B(*)5701 positive giving a rate of 0.26% (CI 0.07% to 0.94%). 
      CONCLUSIONS: HLA-B(*)5701 prevalence was similar to previously reported rates in 
      White HIV-infected subjects but considerably lower than that reported in Black 
      HIV-1-infected subjects, as a result of the large proportion of Black African 
      subjects.
FAU - Orkin, C
AU  - Orkin C
AD  - Department of Infection and Immunity, Barts & the London NHS Trust, London, UK.
FAU - Sadiq, S T
AU  - Sadiq ST
FAU - Rice, L
AU  - Rice L
FAU - Jackson, F
AU  - Jackson F
CN  - UK EPI team
LA  - eng
SI  - ClinicalTrials.gov/NCT00453440
PT  - Journal Article
PT  - Multicenter Study
DEP - 20090924
PL  - England
TA  - HIV Med
JT  - HIV medicine
JID - 100897392
RN  - 0 (Anti-HIV Agents)
RN  - 0 (Dideoxynucleosides)
RN  - 0 (Genetic Markers)
RN  - 0 (HLA-B Antigens)
RN  - 0 (HLA-B*57:01 antigen)
RN  - WR2TIP26VS (abacavir)
SB  - IM
MH  - Adult
MH  - Africa/ethnology
MH  - Aged
MH  - Anti-HIV Agents/adverse effects
MH  - Black People/genetics
MH  - Dideoxynucleosides/adverse effects
MH  - Drug Hypersensitivity/epidemiology/*genetics
MH  - Epidemiologic Studies
MH  - Female
MH  - Genetic Markers
MH  - Genetic Testing/methods
MH  - Genotype
MH  - HIV Infections/drug therapy/*immunology
MH  - HLA-B Antigens/*analysis/genetics
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - United Kingdom/epidemiology
MH  - White People
MH  - Young Adult
EDAT- 2009/09/29 06:00
MHDA- 2010/08/19 06:00
CRDT- 2009/09/29 06:00
PHST- 2009/09/29 06:00 [entrez]
PHST- 2009/09/29 06:00 [pubmed]
PHST- 2010/08/19 06:00 [medline]
AID - HIV762 [pii]
AID - 10.1111/j.1468-1293.2009.00762.x [doi]
PST - ppublish
SO  - HIV Med. 2010 Mar;11(3):187-92. doi: 10.1111/j.1468-1293.2009.00762.x. Epub 2009 
      Sep 24.